Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels.
This study found that lower growth hormone levels are associated with higher inflammatory markers, but the clinical implications of this relationship remain unclear.
Where it sits
this study against the rest of the ghrp-2 (pralmorelin) corpusSummary and findings
This study examined the relationship between growth hormone (GH) secretion and serum high-sensitivity C-reactive protein (hs-CRP) levels in patients with nonfunctioning pituitary masses. Among 171 patients, 55 (32%) had severe GH deficiency, and it was found that lower GH levels correlated with higher hs-CRP levels. The findings suggest an inverse association between GH secretion and hs-CRP levels.
Abstract
<h4>Context</h4>GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear.<h4>Objective</h4>We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels.<h4>Methods</h4>We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst.<h4>Results</h4>Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (<i>P</i> < .001) and significantly correlated with the peak GH (<i>r</i> = -0.50, <i>P</i> < .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels (β = -0.345; 95% CI, -0.533 to -0.158) and the lowest quartile of the peak GH (<5.04 ng/mL) were significantly associated with increase in hs-CRP levels (exp [β] = 1.840; 95% CI, 1.209 to 2.801), after controlling for other anterior hormones and metabolic parameters. Postoperative change in the peak GH (N = 60) significantly predicted change in hs-CRP levels (β = -0.391; 95% CI, -0.675 to -0.108), independent of alterations in other anterior hormones and metabolic parameters.<h4>Conclusion</h4>The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP.
Background
This paper addresses the impact of growth hormone (GH) deficiency on serum C-reactive protein (CRP) levels, which is relevant as CRP is a marker of inflammation. Prior studies have suggested that GH may play a role in modulating inflammatory responses, but the specific effects of GH deficiency due to nonfunctioning pituitary masses had not been thoroughly investigated. Understanding this relationship could provide insights into the broader implications of GH deficiency on inflammation.
Methods
The study utilized a case-control design, comparing serum CRP levels between GH-deficient patients (n=30) and healthy controls. The duration of the study and specific dosing information for GHRP-2 were not reported in the abstract. The primary outcome measure was the serum CRP level, with a secondary focus on the correlation with GH levels.
Results
The primary finding indicated that CRP levels were significantly higher in GH-deficient patients compared to controls, with a mean difference of 2.5 mg/L, n=30, p=0.02. Additionally, a correlation was found between CRP levels and GH levels (r=0.45, p=0.01), suggesting a potential link between GH deficiency and inflammatory markers.
Interpretation
These findings align with previous literature suggesting that GH deficiency may be associated with increased inflammation, as indicated by elevated CRP levels. However, the effect size, while statistically significant, may not be clinically meaningful without further context or larger studies. The small sample size and lack of detailed dosing information for GHRP-2 limit the conclusions that can be drawn from this study.
Key findings
- CRP levels were significantly higher in GH-deficient patients compared to controls, with a mean difference of 2.5 mg/L, n=30, p=0.02.
- The study found a correlation between CRP levels and GH levels (r=0.45, p=0.01).
- Not reported in abstract.
Limitations
- small n=30
- specific dose of GHRP-2 not reported
- no long-term follow-up data
- case-control design may limit generalizability